Buprenorphine Based MAT Programs
Buprenorphine Based MAT Programs has no subcategories
|The structure of the services index and definitions of the terms contained herein were originally published in A Taxonomy of Human Services: A Conceptual Framework with Standardized Terminology and Definitions for the Field by the Information and Referral Federation of Los Angeles County, Inc., 3035 Tyler Ave., El Monte, CA 91731; Copyright (c) 1983, 1987, 1991. No part of this listing of human services terms and definitions may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electrical, mechanical, photocopying, recording or otherwise without the prior written permission of the Information and Referral Federation of Los Angeles County, Inc.|
This file's content displays in the left hand side margin of your Taxonomy - Directory of Services.
Above is the standard disclaimer required by AIRS INFOLINE, please consult locally or with AIRS as to what is appropriate to post for your system Taxonomy.
We do NOT recommend that you use MS Word to edit or manage this file, be sure to seek out a program or application that is a valid web authoring tool to do so.
You will want to be sure to retain the exact file name and extension when editing, saving, and re-uploading this file to your directory.
Medication assisted treatment (MAT) programs that use buprenorphin to help people with an opioid use disorder abstain from or reduce their use of opioids (usually heroin or painkillers such as oxycondin or morphine). Buprenorphine produces a weaker version of effects (including euphoria and respiratory depression) that are associated with full drugs such as heroin and methadone. The effects increase with each dose until at moderate doses they level off, lowering the risk of misuse, dependency and side effects. Treatment occurs in three phases: a medically monitored start-up phase when the patient is in early stages of withdrawal; a stabilization phase after a patient has discontinued or greatly reduced their misuse of the problem drug, no longer has cravings, and experiences few, if any, side effects; and a maintenance phase when a patient is doing well on a steady dose of buprenorphine. The length of time of the maintenance phase is tailored to each patient and could be indefinite. Once an individual is stabilized, an alternative approach would be to go into a medically supervised withdrawal, which makes the transition from a physically dependent state smoother. People then can engage in further rehabilitation—with or without MAT—to prevent a possible relapse. Ideal candidates for opioid dependency treatment with buprenorphine have an opioid use disorder diagnosis, are willing to follow safety precautions for the treatment, have been cleared of any health conflicts with using the drug and have reviewed other treatment options before agreeing to buprenorphine treatment.
Navigation Tips [+/-]